Treatment options for proliferative lupus nephritis: An update of clinical trial evidence

Drugs

Volumn 68, Issue 15, 2008, Pages 2095-2104

  Navaneethan, Sankar D ^a   Viswanathan, Gautham ^b   Strippoli, Giovanni F M ^c,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Department of Medicine   (United States)

^c Mario Negri Sud Consortium ^*  (Italy)

^d Medical Scientific Office   (Sweden)

Author keywords

Azathioprine, therapeutic use; Ciclosporin, therapeutic use; Lupus nephritis, treatment; Mycophenolate mofetil, therapeutic use; Rituximab, therapeutic use

Indexed keywords

ABETIMUS; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RITUXIMAB;

AMENORRHEA; CLINICAL FEATURE; CLINICAL TRIAL; DOSE KIDNEY FUNCTION RELATION; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; GONAD FUNCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRACTICE GUIDELINE; REMISSION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CLINICAL TRIALS AS TOPIC; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; OLIGONUCLEOTIDES;

EID: 53649095941     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868150-00002     Document Type: Review

References (45)

1. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999; 10: 413-24
2. Gruppo Italiano per lo Studio Nefrite Lupica (GISNEL). Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Am J Kidney Dis 1992; 19: 473-9
3. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725
4. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-50
5. Contreras G, Roth D, Pardo V, et al. Lupus nephritis: a clinical review for practicing nephrologists. Clin Nephrol 2002; 57: 95-107
6. Mercado L, Moncole ST, Notch D, et al. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant 2002; 17: 1771-8
7. Houssiau FA. Management of lupus nephritis: an update. J Am Soc Nephrol 2004; 15: 2694-704
8. Lai KN, Tang SC, Mok CC. Treatment for lupus nephritis: a revisit. Nephrology 2005; 10: 180-8
9. Moroni G, Silvani Q, Beniamina G, et al. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant 2007; 22: 2531-253
10. Austin HA, Boumpas DT, Vaughan EM, et al. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995; 10: 1620-8
11. Austin HA, Boumpas DT, Vaughan EM, et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994; 45: 544-50
12. Houssiau FA. Cyclophosphamide in lupus nephritis. Lupus 2005; 14: 53-8
13. Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-9
14. Boumpas DT, Austin III HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-5
15. Gourley MF, Austin III HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 1996; 125: 549-57
16. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-57
17. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-31
18. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998; 41: 831-7
19. Boumpas DT, Austin HA, Vaughan EM, et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366-9
20. Houssiau FA, Lefebvre C, Depresseux G, et al. Trabecular and cortical bone loss in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 244-7
21. Petri M. Infection in systemic lupus erythematosus. Rheum Dis Clin North Am 1998; 24: 423-56
22. Flanc RS, Roberts MA, Strippoli GF, et al. Treatment for lupus nephritis. Cochrane Database Syst Rev 2004; (1): CD002922
23. Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997; 29: 193-9
24. Moore RA, Derry S. Systematic review and meta-analysis of randomized trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006; 8 (6): R182
25. Zhu B, Chen N, Lin Y, et al. Mycophenolate mofetil in induction and maintenance therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007; 22 (7): 1933-42
26. Viswanathan G, Navaneethan SD, Craig J, et al. Mycophenolate mofetil for treatment of diffuse proliferative lupus nephritis: a systematic review. American Society of Nephrology's (ASN) 39th Annual Meeting and Scientific Exposition; 2006 Nov 16-19; San Diego (CA). J Am Soc Nephrol 2006; 17: 572-3A
27. Walsh M, James M, Jayne D, et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007; 2 (5): 968-75
28. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-62
29. Van Bruggen MC, Walgreen B, Rijke TP, et al. Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 1998; 9: 1407-15
30. Dooley MA, Cosio FG, Nachman PH, et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999; 10: 833-9
31. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-80
32. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-28
33. Flores-Suarez LF, Villa RA. Preliminary results of an open label randomized clinical trial comparing MMF vs. intravenous cyclophosphamide (IV-CYC) as induction therapy for severe lupus nephritis [abstract no. 1029]. Program and abstracts of the American College of Rheumatology/Association of Rheumatology Health Professionals 68th Annual Scientific Meeting; 2004 Oct 16-21; San Antonio (TX). Arthritis Rheum 2004; 50 Suppl.: S414
34. Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-84
35. Ong LO, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005; 10 (5): 504-10
36. Moroni G, Doria A, Mosca M, et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006; 1 (5): 925-32
37. Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/ methylprednisolone versus cyclophosphamide in proliferative lupus nephritis: a randomized controlled trial. Kidney Int 2006; 70 (4): 732-42
38. Alarcón-Segovia D, Tumlin JA, Furie RA, et al. LJP 394 Investigator Consortium. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003; 48 (2): 442-54
39. Smith KG, Jones RB, Burns SM, et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006; 54 (9): 2970-82
40. Thatayatikom A, White AJ. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 2006; 5 (1): 18-24
41. Dooley MA, Hogan S, Jennette C, et al. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997; 51: 1188-95
42. Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum 2003; 32: 370-7
43. Preliminary results for phase III study evaluating CellCept in lupus nephritis. A study of CellCept (mycophenolate mofetil) in management of patients with lupus nephritis. Basel: Roche, 2007 Jun 27 [online]. Available from URL: http://www.roche.com/inv-update-2007-06-27 [Accessed 2008 Aug 8]
44. Wang J, Hu W, Xie H, et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus 2007; 16 (9): 707-12
45. ClinicalTrials.gov [online]. Available from URL: http://www. clinicaltrials.gov/ct2/results?.term=lupus+nephritis [Accessed 2008 Aug 8]